![Transparency Market Researchが調査・発行した産業分析レポートです。慢性腎臓病（CKD）向け栄養補助食品の世界市場2022-2031：産業分析、規模、シェア、成長、動向、予測 / Chronic Kidney Disease [CKD] Nutritional Supplement Market (Nutrition Type: Amino Acid Supplements, Vitamin & Mineral Supplements, Probiotics, Prebiotics/Fibers, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031 / MRC2211A110資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/report-contents-57.gif) | • レポートコード：MRC2211A110 • 出版社/出版日：Transparency Market Research / 2022年8月 • レポート形態：英文、PDF、217ページ • 納品方法：Eメール • 産業分類：食品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トレンスペアレンシーマーケットリサーチ社の当調査レポートでは、世界の慢性腎臓病（CKD）向け栄養補助食品市場を総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、栄養種類別（アミノ酸サプリメント、ビタミン＆ミネラルサプリメント、プロバイオティクス、プレバイオティクス/繊維、その他）分析、剤形別（カプセル、液体、粉末、その他）分析、FSMP管理モード別（経口栄養（ON）、経腸栄養（EN））分析、流通チャネル別（病院薬局、小売薬局、オンラインストア）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容を掲載しています。なお、当書には、Abbott Laboratories、Ajanta Pharma Limited、Fresenius Kabi AG、Hexagon Nutrition Limited、Mankind Pharma Ltd.、Nestlé S.A.、Nutricia Limited (Danone S.A.)、PRINE Health MSO, LLC、RPG Life Sciences Limitedなどの企業情報が含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の慢性腎臓病（CKD）向け栄養補助食品市場規模：栄養種類別 - アミノ酸サプリメントの市場規模 - ビタミン＆ミネラルサプリメントの市場規模 - プロバイオティクスの市場規模 - プレバイオティクス/繊維の市場規模 - その他栄養補助食品の市場規模 ・世界の慢性腎臓病（CKD）向け栄養補助食品市場規模：剤形別 - カプセル状栄養補助食品の市場規模 - 液状栄養補助食品の市場規模 - 粉末状栄養補助食品の市場規模 - その他栄養補助食品の市場規模 ・世界の慢性腎臓病（CKD）向け栄養補助食品市場規模：FSMP管理モード別 - 経口栄養（ON）の市場規模 - 経腸栄養（EN）の市場規模 ・世界の慢性腎臓病（CKD）向け栄養補助食品市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンラインストアチャネルの市場規模 ・世界の慢性腎臓病（CKD）向け栄養補助食品市場規模：地域別 - 北米の慢性腎臓病（CKD）向け栄養補助食品市場規模 - ヨーロッパの慢性腎臓病（CKD）向け栄養補助食品市場規模 - アジア太平洋の慢性腎臓病（CKD）向け栄養補助食品市場規模 - 中南米の慢性腎臓病（CKD）向け栄養補助食品市場規模 - 中東・アフリカの慢性腎臓病（CKD）向け栄養補助食品市場規模 ・競争状況 |
Chronic Kidney Disease Nutritional Supplement Market – Scope of Report
TMR’s report on the global chronic kidney disease nutritional supplement market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global chronic kidney disease nutritional supplement market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global chronic kidney disease nutritional supplement market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the chronic kidney disease nutritional supplement market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global chronic kidney disease nutritional supplement market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global chronic kidney disease nutritional supplement market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global chronic kidney disease nutritional supplement market.
The report delves into the competitive landscape of the global chronic kidney disease nutritional supplement market. Key players operating in the global chronic kidney disease nutritional supplement market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global chronic kidney disease nutritional supplement market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market chronic kidney disease nutritional supplement.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Chronic Kidney Disease Nutritional Supplement Market
4. Market Overview
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Average Pricing Per Nutrition Type
5.2. Porter’s Five Force Analysis
5.3. COVID-19 Impact Analysis
5.4. Prevalence of Chronic Kidney Diseases Globally
6. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Nutrition Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Nutrition Type, 2017–2031
6.3.1. Amino Acid Supplements
6.3.1.1. Alpha-Ketoanalogue Supplements
6.3.1.2. Alpha Lipoic Acid Supplements
6.3.1.3. Others
6.3.2. Vitamin & Mineral Supplements
6.3.3. Probiotics
6.3.4. Prebiotics/Fibers
6.3.5. Others
6.4. Market Attractiveness Analysis, by Nutrition Type
7. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Dosage Form
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Dosage Form, 2017–2031
7.3.1. Capsule Form
7.3.2. Liquid Form
7.3.3. Powder Form
7.3.4. Others
7.4. Market Attractiveness Analysis, by Dosage Form
8. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by FSMP Mode of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by FSMP Mode of Administration, 2017–2031
8.3.1. Oral Nutrition (ON)
8.3.2. Enteral Nutrition (EN)
8.4. Market Attractiveness Analysis, by FSMP Mode of Administration
9. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by CKD Stage
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by CKD Stage, 2017–2031
9.3.1. Pre-dialysis Stage 1-2
9.3.2. Pre-dialysis Stage 3-5
9.3.3. Dialysis
9.3.4. End-stage Renal Disease
9.4. Market Attractiveness Analysis, by CKD Stage
10. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Stores
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Nutrition Type, 2017–2031
12.2.1. Amino Acid Supplements
12.2.1.1. Alpha-Ketoanalogue Supplements
12.2.1.2. Alpha Lipoic Acid Supplements
12.2.1.3. Others
12.2.2. Vitamin & Mineral Supplements
12.2.3. Probiotics
12.2.4. Prebiotics/Fibers
12.2.5. Others
12.3. Market Value Forecast, by Dosage Form, 2017–2031
12.3.1. Capsule Form
12.3.2. Liquid Form
12.3.3. Powder Form
12.3.4. Others
12.4. Market Value Forecast, by FSMP Mode of Administration, 2017–2031
12.4.1. Oral Nutrition (ON)
12.4.2. Enteral Nutrition (EN)
12.5. Market Value Forecast, by CKD Stage, 2017–2031
12.5.1. Pre-dialysis Stage 1-2
12.5.2. Pre-dialysis Stage 3-5
12.5.3. Dialysis
12.5.4. End-stage Renal Disease
12.6. Market Value Forecast, by Distribution Channel, 2017–2031
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Stores
12.7. Market Value Forecast, by Country, 2017–2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Nutrition Type
12.8.2. By Dosage Form
12.8.3. By FSMP Mode of Administration
12.8.4. By CKD stage
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Nutrition Type, 2017–2031
13.2.1. Amino Acid Supplements
13.2.1.1. Alpha-Ketoanalogue Supplements
13.2.1.2. Alpha Lipoic Acid Supplements
13.2.1.3. Others
13.2.2. Vitamin & Mineral Supplements
13.2.3. Probiotics
13.2.4. Prebiotics/Fibers
13.2.5. Others
13.3. Market Value Forecast, by Dosage Form, 2017–2031
13.3.1. Capsule Form
13.3.2. Liquid Form
13.3.3. Powder Form
13.3.4. Others
13.4. Market Value Forecast, by FSMP Mode of Administration, 2017–2031
13.4.1. Oral Nutrition (ON)
13.4.2. Enteral Nutrition (EN)
13.5. Market Value Forecast, by CKD Stage, 2017–2031
13.5.1. Pre-dialysis Stage 1-2
13.5.2. Pre-dialysis Stage 3-5
13.5.3. Dialysis
13.5.4. End-stage Renal Disease
13.6. Market Value Forecast, by Distribution Channel, 2017–2031
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Stores
13.7. Market Value Forecast By Country/Sub-region, 2017–2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Spain
13.7.5. Italy
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Nutrition Type
13.8.2. By Dosage Form
13.8.3. By FSMP Mode of Administration
13.8.4. By CKD stage
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Nutrition Type, 2017–2031
14.2.1. Amino Acid Supplements
14.2.1.1. Alpha-Ketoanalogue Supplements
14.2.1.2. Alpha Lipoic Acid Supplements
14.2.1.3. Others
14.2.2. Vitamin & Mineral Supplements
14.2.3. Probiotics
14.2.4. Prebiotics/Fibers
14.2.5. Others
14.3. Market Value Forecast, by Dosage Form, 2017–2031
14.3.1. Capsule Form
14.3.2. Liquid Form
14.3.3. Powder Form
14.3.4. Others
14.4. Market Value Forecast, by FSMP Mode of Administration, 2017–2031
14.4.1. Oral Nutrition (ON)
14.4.2. Enteral Nutrition (EN)
14.5. Market Value Forecast, by CKD Stage, 2017–2031
14.5.1. Pre-dialysis Stage 1-2
14.5.2. Pre-dialysis Stage 3-5
14.5.3. Dialysis
14.5.4. End-stage Renal Disease
14.6. Market Value Forecast, by Distribution Channel, 2017–2031
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Stores
14.7. Market Value Forecast, by Country/Sub-region, 2017–2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Taiwan
14.7.5. Australia & New Zealand
14.7.6. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Nutrition Type
14.8.2. By Dosage Form
14.8.3. By FSMP Mode of Administration
14.8.4. By CKD stage
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Nutrition Type, 2017–2031
15.2.1. Amino Acid Supplements
15.2.1.1. Alpha-Ketoanalogue Supplements
15.2.1.2. Alpha Lipoic Acid Supplements
15.2.1.3. Others
15.2.2. Vitamin & Mineral Supplements
15.2.3. Probiotics
15.2.4. Prebiotics/Fibers
15.2.5. Others
15.3. Market Value Forecast, by Dosage Form, 2017–2031
15.3.1. Capsule Form
15.3.2. Liquid Form
15.3.3. Powder Form
15.3.4. Others
15.4. Market Value Forecast, by FSMP Mode of Administration, 2017–2031
15.4.1. Oral Nutrition (ON)
15.4.2. Enteral Nutrition (EN)
15.5. Market Value Forecast, by CKD Stage, 2017–2031
15.5.1. Pre-dialysis Stage 1-2
15.5.2. Pre-dialysis Stage 3-5
15.5.3. Dialysis
15.5.4. End-stage Renal Disease
15.6. Market Value Forecast, by Distribution Channel, 2017–2031
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Online Stores
15.7. Market Value Forecast, by Country/Sub-region, 2017–2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Nutrition Type
15.8.2. By Dosage Form
15.8.3. By FSMP Mode of Administration
15.8.4. By CKD stage
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Nutrition Type, 2017–2031
16.2.1. Amino Acid Supplements
16.2.1.1. Alpha-Ketoanalogue Supplements
16.2.1.2. Alpha Lipoic Acid Supplements
16.2.1.3. Others
16.2.2. Vitamin & Mineral Supplements
16.2.3. Probiotics
16.2.4. Prebiotics/Fibers
16.2.5. Others
16.3. Market Value Forecast, by Dosage Form, 2017–2031
16.3.1. Capsule Form
16.3.2. Liquid Form
16.3.3. Powder Form
16.3.4. Others
16.4. Market Value Forecast, by FSMP Mode of Administration, 2017–2031
16.4.1. Oral Nutrition (ON)
16.4.2. Enteral Nutrition (EN)
16.5. Market Value Forecast, by CKD Stage, 2017–2031
16.5.1. Pre-dialysis Stage 1-2
16.5.2. Pre-dialysis Stage 3-5
16.5.3. Dialysis
16.5.4. End-stage Renal Disease
16.6. Market Value Forecast, by Distribution Channel, 2017–2031
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Online Stores
16.7. Market Value Forecast, by Country/Sub-region, 2017–2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Nutrition Type
16.8.2. By Dosage Form
16.8.3. By FSMP Mode of Administration
16.8.4. By CKD stage
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (by tier and size of companies)
17.2. Market Share Analysis/Ranking, by Company, 2021
17.3. Company Profiles
17.3.1. Abbott Laboratories
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. Strategic Overview
17.3.1.5. SWOT Analysis
17.3.2. Ajanta Pharma Limited
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. Strategic Overview
17.3.2.5. SWOT Analysis
17.3.3. Fresenius Kabi AG
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. Strategic Overview
17.3.3.5. SWOT Analysis
17.3.4. Hexagon Nutrition Limited
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.5. Mankind Pharma Ltd.
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Strategic Overview
17.3.5.4. SWOT Analysis
17.3.6. Nestlé S.A.
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. Strategic Overview
17.3.6.5. SWOT Analysis
17.3.7. Nutricia Limited (Danone S.A.)
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. Strategic Overview
17.3.7.5. SWOT Analysis
17.3.8. PRINE Health MSO, LLC
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. SWOT Analysis
17.3.9. RPG Life Sciences Limited
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. Strategic Overview
17.3.9.5. SWOT Analysis
Table 01: Average Pricing Per Nutrition Type
Table 02: Average Pricing Per Nutrition Type
Table 03: Prevalence of Chronic Kidney Diseases Globally
Table 04: Global Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Nutrition Type, 2017–2031
Table 05: Global Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Amino Acid Supplements, 2017–2031
Table 06: Global Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Dosage Form , 2017–2031
Table 07: Global Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by FSMP Mode of Administration, 2017–2031
Table 08: Global Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by CKD Stage, 2017–2031
Table 09: Global Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 10: Global Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 11: North America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Nutrition Type, 2017–2031
Table 12: North America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Amino Acid Supplements, 2017–2031
Table 13: North America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 14: North America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by FSMP Mode of Administration, 2017–2031
Table 15: North America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by CKD Stage, 2017–2031
Table 16: North America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: North America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 18: Europe Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Nutrition Type, 2017–2031
Table 19: Europe Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Amino Acid Supplements, 2017–2031
Table 20: Europe Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 21: Europe Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by FSMP Mode of Administration, 2017–2031
Table 22: Europe Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by CKD Stage, 2017–2031
Table 23: Europe Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 24: Europe Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 25: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Nutrition Type, 2017–2031
Table 26: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Amino Acid Supplements, 2017–2031
Table 27: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 28: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by FSMP Mode of Administration, 2017–2031
Table 29: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by CKD Stage, 2017–2031
Table 30: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 31: Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 32: Latin America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Nutrition Type, 2017–2031
Table 33: Latin America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Amino Acid Supplements, 2017–2031
Table 34: Latin America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Dosage Form , 2017–2031
Table 35: Latin America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by FSMP Mode of Administration, 2017–2031
Table 36: Latin America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by CKD Stage, 2017–2031
Table 37: Latin America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 38: Latin America Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 39: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Nutrition Type, 2017–2031
Table 40: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Amino Acid Supplements, 2017–2031
Table 41: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Dosage Form , 2017–2031
Table 42: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by FSMP Mode of Administration, 2017–2031
Table 43: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by CKD Stage, 2017–2031
Table 44: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 45: Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031